Stem cell therapy is used in two very different ways: as an established hospital treatment for certain blood cancers and blood disorders, and as an emerging area being explored for tissue repair in other conditions. Knowing which “type” you’re reading about matters, because the evidence, regulation, and expected outcomes aren’t the same.
The established use: treating blood cancers and serious blood disorders
In mainstream medicine, stem cells are most clearly used in stem cell (bone marrow) transplants. Doctors use them to replace damaged or diseased blood-forming cells, often after high-dose chemotherapy or radiotherapy. This can treat conditions like leukaemia and lymphoma, plus other serious blood disorders.
This is the area where stem cell treatment has a long track record in regulated clinical care. It’s also why the term carries so much weight — because in this setting, outcomes and pathways are well defined.
The emerging use: research and “regenerative” approaches
Outside blood conditions, researchers are studying how different types of stem cells might help repair or replace damaged tissues. This includes areas such as neurological disease, heart disease, and joint conditions — but these are not all “ready-made” clinical solutions.
In musculoskeletal care, what people call stem cell therapy is often discussed alongside other “orthobiologic” injections. The goal is usually symptom improvement (pain and function) by influencing inflammation and the joint environment, rather than rebuilding a severely damaged joint overnight. The British Orthopaedic Association also cautions that the term “stem cells” can mislead people into thinking injected cells will simply turn into new tissue, which has not been shown for currently available preparations.
What it’s used for in joint pain: what patients should know
For knee osteoarthritis (and similar joint problems), many people look into stem cell therapy because they want an option that feels less invasive than surgery. But it’s important to match hope with evidence.
NHS England’s decision support tool for knee osteoarthritis states there is no good evidence that stem cell therapy helps with osteoarthritis pain (and it makes the same point about PRP in that context).
So, in practical terms, it’s often “used for” these patient goals:
- exploring whether symptoms can improve without major surgery,
- understanding what’s realistic for your stage of disease,
- and building a plan that includes diagnosis, rehab, and risk awareness (not just an injection).
Why regulation matters in the UK
Because “stem cell therapy” can mean different products and processes, governance matters. In the UK, many cell-based products fall under Advanced Therapy Medicinal Product (ATMP) rules, with defined routes for licensing and supply.
For patients, the point is simple: you want clarity on what is being offered, how it’s regulated, what evidence supports it for your condition, and what outcomes are realistic. If a provider guarantees results or avoids specifics, treat that as a sign to slow down and ask better questions.
Conclusion
Stem cell therapy is used most clearly in hospitals for blood cancers and serious blood disorders, where stem cell transplants are a standard, regulated treatment. In other areas — including joint pain — stem cell therapy is an evolving space, and for osteoarthritis the NHS notes there is no good evidence it helps osteoarthritis pain, so decisions should be careful and evidence-led.
If you’re exploring options for hip or knee pain, read our related posts on osteoarthritis and treatment planning, or get in touch to discuss whether a specialist assessment could help you choose the most sensible next step.
Sign in to leave a comment.